TG Therapeutics TGTX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's stock-based comp?
- TG Therapeutics (TGTX) reported stock-based comp of $19.95M in Q1 2026.
- How has TG Therapeutics's stock-based comp changed year-over-year?
- TG Therapeutics's stock-based comp increased by 33.2% year-over-year, from $14.97M to $19.95M.
- What is the long-term trend for TG Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), TG Therapeutics's stock-based comp has grown at a 1.4% compound annual growth rate (CAGR), from $61.27M to $64.67M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock instead of cash.
- How do you interpret stock-based comp?
- Higher levels indicate significant dilution risk for shareholders but may be necessary to attract top talent.
- How does stock-based comp compare across companies?
- High in growth-stage biotech companies that rely on equity to preserve cash reserves.